Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management.

J Am Acad Orthop Surg Glob Res Rev

From the Department of Orthopaedic Surgery, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico (Dr. Mangual-Pérez, Dr. Tresgallo-Parés, Dr. Ramírez-González, Dr. Torres-Lugo, and Dr. Lojo-Sojo); the School of Medicine, Universidad Central del Caribe, Bayamon, Puerto Rico (Dr. Rivera-Dones and Dr. Rivera-Rodríguez); and the School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico (Dr. Claudio-Marcano).

Published: July 2022

Introduction: The current rate of opioid prescription is disquieting because of their high abuse potential, adverse effects, and thousands of overdose deaths. This situation imposes urgency in seeking alternatives for adequate pain management. From this perspective, this study aimed to evaluate the experience and the perceived analgesic efficacy of medical cannabis in managing the pain associated with musculoskeletal conditions.

Methods: A 28-question survey was distributed to patients at a major medical cannabis center in Puerto Rico for 2 months. Demographics, medical history, cannabis usage, cannabis use perspective, and analgesic efficacy were assessed in the questionnaire.

Results: One hundred eighty-four patients completed our survey. The majority (67%) were males, and the participants' average age was 38 years. This study showed an average pain reduction score of 4.02 points on the Numeric Rating Scale among all the participants. Those with musculoskeletal conditions reported a notable average pain reduction score of 4.47 points. In addition, 89% of the participants considered medical cannabis to be more effective than narcotics for adequate pain management.

Conclusions: This study demonstrated that the use of medical cannabis among patients with musculoskeletal conditions effectively reduced pain levels based on their Numeric Rating Scale reported scores.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263487PMC
http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00055DOI Listing

Publication Analysis

Top Keywords

medical cannabis
20
pain management
8
adequate pain
8
analgesic efficacy
8
average pain
8
pain reduction
8
reduction score
8
numeric rating
8
rating scale
8
musculoskeletal conditions
8

Similar Publications

This study investigated trends in suspected cannabinoid hyperemesis syndrome (CHS)-related emergency department visits among youth (15-24 years old) in the United States between 2006 and 2020. Using data from the Nationwide Emergency Room Sample, over 55,000 suspected CHS-related visits were identified, with an average annual increase of 28.1% per year.

View Article and Find Full Text PDF

Young men who have sex with men (YMSM) have high rates of substance use, which increases their risk for HIV. Digital Health Interventions (DHI) have the potential to address HIV risk overall and reduce harms in the context of substance use. However, there is limited research on how YMSM with different substance use patterns respond to HIV DHIs and how these programs impact participant outcomes.

View Article and Find Full Text PDF

The association of medical cannabis use with quality of life in Illinois' opioid alternative pilot program.

J Epidemiol Popul Health

January 2025

Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Center of Innovation for Complex Chronic Healthcare, Hines VA Hospital, Hines, IL, United States.

Background: In Illinois, the Opioid Alternative Pilot Program (OAPP) was launched to expand access to medical cannabis to use as a direct substitute for opioids. Although therapeutic benefits have been reported in reducing opioid use, there is an absence of literature that examines how medical cannabis use impacts an individual's quality of life (QoL). This study examines the association of medical cannabis use with QoL among the first enrollees in OAPP.

View Article and Find Full Text PDF

Introduction: The official implementation of pharmaceutical-grade cannabis raw materials for medicinal use has permitted doctors to prescribe and pharmacists to prepare cannabis-based formulations. The objective of the pharmaceutical development and manufacturing process optimization work was to propose a suppository formulation containing doses of 25 mg and 50 mg of tetra-hydrocannabinol (∆-9-THC) as an alternative to existing inhalable or orally administered formulations. The formulation could be used for rectal or vaginal administration, thereby providing dosage control in the treatment of endometriosis and other conditions involving pain.

View Article and Find Full Text PDF

Background: Intravenous nanoemulsions (NEs) are gaining attention as potential delivery systems for poorly water-soluble substances like cannabidiol (CBD). This study aimed to develop novel NEs based on CBD-enriched hemp oils and evaluate their physiochemical properties.

Methods: The stability of hemp oils enriched with various concentrations of CBD (0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!